Revealing the mechanism of nucleotide selection, addition and proofreading of the SARS-coronavirus replication transcription complex at the single molecule level
Revealing the mechanism of nucleotide selection, addition and proofreading of the SARS-coronavirus replication transcription complex at the single molecule level
批准号:
447835095
负责人:
Dr. David Dulin, Ph.D.
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
--
资助国家:
德国
项目状态:
未结题
起止时间:
中文摘要
RNA病毒是一组非常多样化的病原体。这是特别强调的各种各样的因素参与其复制转录复合物(RTC)和他们的巧妙的信使和基因组RNA合成的模式。病毒RNA合成由RTC确保,RTC还通过核苷酸错配和促进病毒基因组重组来确保进化。然而,RTC的突变率太高而不能产生长基因组单链阳性RNA病毒如冠状病毒(CoV)(~30 kb)的感染性病毒体。因此,CoV已经通过编码RNA校正酶(即3'至5'外切核酸酶)来解决了这个问题,以校正过量的突变,这也保护人类致病性CoV,例如中东呼吸综合征(MERS),严重急性呼吸综合征(SARS)和新型冠状病毒2019(COVID-19)免受靶向RTC的抗病毒核苷酸类似物的影响。了解CoV核酸外切酶如何检测掺入后的核苷酸错配和类似物,仍然是开发更有效的抗病毒药物的重要研究课题。为了表征核苷酸错配和类似物掺入的动力学并推导动力学模型,标准批量生物化学测定使用短模板(~10 nt)并且没有竞争性核苷酸,这不是现实的条件。使用高通量磁镊和双链酶长模板,我将能够监测SARS冠状病毒RTC核苷酸错配和类似物掺入的动力学特征,在单分子水平上,接近单碱基分辨率,并在饱和浓度下与四种天然核苷酸竞争。SARS-CoV RTC可以说是最著名的冠状病毒RTC,CoV RTC的高度保守性将使我的提议的未来结果可扩展到其他CoV,如MERS和COVID-19。我将推导出一个完整的动力学模型,描述核苷酸错配掺入的动力学,并使用SARS-CoV RTC表征市售核苷酸类似物的作用机制。
英文摘要
RNA viruses are a very diverse group of pathogens. This is particularly underlined by the large variety of factors involved in their replication transcription complex (RTC) and their artfulness in modes of messenger and genomic RNA synthesis. Viral RNA synthesis is ensured by the RTC, which also ensures evolution through nucleotide mismatch incorporations and by promoting viral genome recombination. However, the mutation rate of the RTC is too high to generate infectious virions for long genome single stranded positive RNA viruses, such as coronavirus (CoV) (~30 kb). Therefore, CoV have solved this problem by encoding an RNA proofreading enzyme, i.e. a 3’ to 5’ exonuclease to correct the excessive numbers of mutations, which also protects human pathogenic CoV’s, e.g. the Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS) and new coronavirus 2019 (COVID-19) from antiviral nucleotide analogues targeting the RTC. Understanding how CoV exonuclease senses nucleotide mismatch and analogues after incorporation remains an important research topic to develop more efficient antiviral drugs. To characterize the kinetics of nucleotide mismatch and analogues incorporation and derive a kinetic model, standard bulk biochemistry assays use short templates (~10 nt) and no competing nucleotides, which are not realistic conditions. Using high throughput magnetic tweezers and kilobases long templates, I will be able to monitor the kinetic signature of SARS-CoV RTC nucleotide mismatch and analogue incorporation at the single molecule level with near single base resolution and in competition with the four natural nucleotides at saturating concentrations. SARS-CoV RTC is arguably the best-known coronavirus RTC, and the high degree of conservation of CoV RTC will make the future results of my proposal extendable to other CoVs, such as MERS and COVID-19. I will derive a complete kinetic model describing the kinetics of nucleotide mismatch incorporation and characterize the mechanism of action of commercially available nucleotide analogues using SARS-CoV RTC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Revealing the mechanism of directional transcription termination at the single molecule level for the human mitochondrial transcription complex
-
批准号:436178547
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Dr. David Dulin, Ph.D.
-
依托单位:
Determinants and dynamics of RNA polymerase I transcription initiation
-
批准号:448328357
-
项目类别:Research Grants
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Dr. David Dulin, Ph.D.
-
依托单位:
国内基金
海外基金
登录
查看更多内容
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
-
批准号:82371634
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵福军
-
依托单位:
PRNP调控巨噬细胞M2极化并减弱吞噬功能促进子宫内膜异位症进展的机制研究
-
批准号:82371651
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵栋
-
依托单位:
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
-
批准号:82370798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王晓
-
依托单位:
生物钟核受体Rev-erbα在缺血性卒中神经元能量代谢中的改善作用及机制研究
-
批准号:82371332
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:胡琴
-
依托单位:
TIPE2调控巨噬细胞M2极化改善睑板腺功能障碍的作用机制研究
-
批准号:82371028
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵慧
-
依托单位:
慢性炎症诱发骨丢失的机制及外泌体靶向治疗策略研究
-
批准号:82370889
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:傅德皓
-
依托单位:
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
-
批准号:82371616
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨成
-
依托单位:
超声驱动压电效应激活门控离子通道促眼眶膜内成骨的作用及机制研究
-
批准号:82371103
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:阮静
-
依托单位:
5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
-
批准号:82372743
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈卓佳
-
依托单位:
骨髓ISG+NAMPT+中性粒细胞介导抗磷脂综合征B细胞异常活化的机制研究
-
批准号:82371799
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:杨程德
-
依托单位: